Previous 10 | Next 10 |
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022. A webcast of th...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Akebia Therapeutics (NASDAQ: AKBA ) stock got off to a resounding start today, at one point seeing a 45% jump from yesterday’s close. Akebia specializes in treatments for com...
- 73 Ambulatory DMD Patients Enrolled - - Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients...
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event...
Do You Have These Top Biotech Stocks On Your Watchlist? Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward sector to invest in. This is an industry that includes compa...
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Contin...
Shares of FibroGen (NASDAQ:FGEN) have added 25.3% to $9.95 in Tuesday afternoon trading, after the biopharmaceutical company posted Q1 2022 earnings that beat estimates and raised its 2022 ending cash balance guidance. FGEN's Q1 GAAP EPS of -$0.68 beat estimates by $0.24, and r...
FibroGen, Inc. (FGEN) Q1 2022 Earnings Conference Call May 09, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno – Chief Executive Officer Mark Eisner – Chief Medical Officer Juan Graham – Chief Financial Off...
FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. Based on our latest forecast, we estimate a 2022 ending cash balance of $310-340 million. For further details see: FibroGen GAAP EPS of -$0.68 beats by $0.24, rev...
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction S...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...